Statistical analyses showed that the combination of anti-PD1 + L-DOS47 significantly reduced tumor growth when compared with the control (p = 0.01) and L-DOS47 monotherapy (p = 0.04) groups at week 2 (days 13–14), and it differed significantly from the anti-PD1 monotherapy at weeks 3 and 4 (days 20–21 and 27–28). The gene discussed is PDCD1; the disease is neoplasm.